A comprehensive investigation of PRMT5 in the prognosis and ion channel features of lung cancer

The increasing incidence and mortality associated with lung cancer (LC) is a significant global health challenge. The underlying mechanisms contributing to LC remain inadequately understood. However, emerging evidence suggests that the epigenetic modifier protein arginine methyltransferase 5 (PRMT5)...

Full description

Saved in:
Bibliographic Details
Main Authors: Yan Wang, Daifang Chu, Haichao Li, Jiangjiang Fan, Ximing Zhu, Yulong Ma, Zhongping Gu, Nianlin Xie, Pengyu Jing
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-11-01
Series:Frontiers in Oncology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1478672/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846150279948402688
author Yan Wang
Daifang Chu
Haichao Li
Jiangjiang Fan
Ximing Zhu
Yulong Ma
Zhongping Gu
Nianlin Xie
Pengyu Jing
author_facet Yan Wang
Daifang Chu
Haichao Li
Jiangjiang Fan
Ximing Zhu
Yulong Ma
Zhongping Gu
Nianlin Xie
Pengyu Jing
author_sort Yan Wang
collection DOAJ
description The increasing incidence and mortality associated with lung cancer (LC) is a significant global health challenge. The underlying mechanisms contributing to LC remain inadequately understood. However, emerging evidence suggests that the epigenetic modifier protein arginine methyltransferase 5 (PRMT5) plays a complex role in various cellular processes, including DNA repair, gene transcription, and alternative splicing, through its function in catalyzing the symmetric dimethylation of both histone and non-histone proteins. In this study, we examined the functional role of PRMT5 utilizing LC-related datasets (GSE30219, GSE50081, and TCGA LC cohort) through a series of analyses. Our findings revealed that PRMT5 was significantly overexpressed in LC samples compared to normal tissues and was correlated with overall survival and disease-free survival rates. Additionally, PRDM1 was identified as a key protein exhibiting a strong interaction with PRMT5. The prognostic model that integrated PRMT5 with clinical factors demonstrated robust performance in assessing survival outcomes. Elevated levels of PRMT5 were associated with poor prognosis in LC, as evidenced by analyses of the GSE30219, GSE50081, and TCGA-LC datasets. Furthermore, we identified 27 ion channel (IC) genes exhibited a correlation with PRMT5 in lung adenocarcinoma (LUAD), of which 9 genes were identified as statistically significant with KM survival analysis. Strikingly, all of the 9 genes, including LRRC8A, the same as PRMT5, were associated with poor prognosis in LUAD. Our research highlights the potential of PRMT5 as a novel prognostic biomarker and its relationship with IC genes in LC.
format Article
id doaj-art-e2ce08f34d144afc8f95d09322218ca1
institution Kabale University
issn 2234-943X
language English
publishDate 2024-11-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Oncology
spelling doaj-art-e2ce08f34d144afc8f95d09322218ca12024-11-29T05:10:24ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2024-11-011410.3389/fonc.2024.14786721478672A comprehensive investigation of PRMT5 in the prognosis and ion channel features of lung cancerYan Wang0Daifang Chu1Haichao Li2Jiangjiang Fan3Ximing Zhu4Yulong Ma5Zhongping Gu6Nianlin Xie7Pengyu Jing8Department of Thoracic Surgery, The Second Affiliated Hospital, Air Force Medical University, Xi’an, ChinaDepartment of Pulmonary and Critical Care Medicine, The Second Affiliated Hospital, Air Force Medical University, Xi’an, ChinaDepartment of Thoracic Surgery, The Second Affiliated Hospital, Air Force Medical University, Xi’an, ChinaDepartment of Thoracic Surgery, The Second Affiliated Hospital, Air Force Medical University, Xi’an, ChinaDepartment of Thoracic Surgery, The Second Affiliated Hospital, Air Force Medical University, Xi’an, ChinaDepartment of Thoracic Surgery, Yicheng County People’s Hospital, Linfen, Shanxi, ChinaDepartment of Thoracic Surgery, The Second Affiliated Hospital, Air Force Medical University, Xi’an, ChinaDepartment of Thoracic Surgery, The Second Affiliated Hospital, Air Force Medical University, Xi’an, ChinaDepartment of Thoracic Surgery, The Second Affiliated Hospital, Air Force Medical University, Xi’an, ChinaThe increasing incidence and mortality associated with lung cancer (LC) is a significant global health challenge. The underlying mechanisms contributing to LC remain inadequately understood. However, emerging evidence suggests that the epigenetic modifier protein arginine methyltransferase 5 (PRMT5) plays a complex role in various cellular processes, including DNA repair, gene transcription, and alternative splicing, through its function in catalyzing the symmetric dimethylation of both histone and non-histone proteins. In this study, we examined the functional role of PRMT5 utilizing LC-related datasets (GSE30219, GSE50081, and TCGA LC cohort) through a series of analyses. Our findings revealed that PRMT5 was significantly overexpressed in LC samples compared to normal tissues and was correlated with overall survival and disease-free survival rates. Additionally, PRDM1 was identified as a key protein exhibiting a strong interaction with PRMT5. The prognostic model that integrated PRMT5 with clinical factors demonstrated robust performance in assessing survival outcomes. Elevated levels of PRMT5 were associated with poor prognosis in LC, as evidenced by analyses of the GSE30219, GSE50081, and TCGA-LC datasets. Furthermore, we identified 27 ion channel (IC) genes exhibited a correlation with PRMT5 in lung adenocarcinoma (LUAD), of which 9 genes were identified as statistically significant with KM survival analysis. Strikingly, all of the 9 genes, including LRRC8A, the same as PRMT5, were associated with poor prognosis in LUAD. Our research highlights the potential of PRMT5 as a novel prognostic biomarker and its relationship with IC genes in LC.https://www.frontiersin.org/articles/10.3389/fonc.2024.1478672/fulllung cancerPRMT5prognosisepigeneticsion channel genes
spellingShingle Yan Wang
Daifang Chu
Haichao Li
Jiangjiang Fan
Ximing Zhu
Yulong Ma
Zhongping Gu
Nianlin Xie
Pengyu Jing
A comprehensive investigation of PRMT5 in the prognosis and ion channel features of lung cancer
Frontiers in Oncology
lung cancer
PRMT5
prognosis
epigenetics
ion channel genes
title A comprehensive investigation of PRMT5 in the prognosis and ion channel features of lung cancer
title_full A comprehensive investigation of PRMT5 in the prognosis and ion channel features of lung cancer
title_fullStr A comprehensive investigation of PRMT5 in the prognosis and ion channel features of lung cancer
title_full_unstemmed A comprehensive investigation of PRMT5 in the prognosis and ion channel features of lung cancer
title_short A comprehensive investigation of PRMT5 in the prognosis and ion channel features of lung cancer
title_sort comprehensive investigation of prmt5 in the prognosis and ion channel features of lung cancer
topic lung cancer
PRMT5
prognosis
epigenetics
ion channel genes
url https://www.frontiersin.org/articles/10.3389/fonc.2024.1478672/full
work_keys_str_mv AT yanwang acomprehensiveinvestigationofprmt5intheprognosisandionchannelfeaturesoflungcancer
AT daifangchu acomprehensiveinvestigationofprmt5intheprognosisandionchannelfeaturesoflungcancer
AT haichaoli acomprehensiveinvestigationofprmt5intheprognosisandionchannelfeaturesoflungcancer
AT jiangjiangfan acomprehensiveinvestigationofprmt5intheprognosisandionchannelfeaturesoflungcancer
AT ximingzhu acomprehensiveinvestigationofprmt5intheprognosisandionchannelfeaturesoflungcancer
AT yulongma acomprehensiveinvestigationofprmt5intheprognosisandionchannelfeaturesoflungcancer
AT zhongpinggu acomprehensiveinvestigationofprmt5intheprognosisandionchannelfeaturesoflungcancer
AT nianlinxie acomprehensiveinvestigationofprmt5intheprognosisandionchannelfeaturesoflungcancer
AT pengyujing acomprehensiveinvestigationofprmt5intheprognosisandionchannelfeaturesoflungcancer
AT yanwang comprehensiveinvestigationofprmt5intheprognosisandionchannelfeaturesoflungcancer
AT daifangchu comprehensiveinvestigationofprmt5intheprognosisandionchannelfeaturesoflungcancer
AT haichaoli comprehensiveinvestigationofprmt5intheprognosisandionchannelfeaturesoflungcancer
AT jiangjiangfan comprehensiveinvestigationofprmt5intheprognosisandionchannelfeaturesoflungcancer
AT ximingzhu comprehensiveinvestigationofprmt5intheprognosisandionchannelfeaturesoflungcancer
AT yulongma comprehensiveinvestigationofprmt5intheprognosisandionchannelfeaturesoflungcancer
AT zhongpinggu comprehensiveinvestigationofprmt5intheprognosisandionchannelfeaturesoflungcancer
AT nianlinxie comprehensiveinvestigationofprmt5intheprognosisandionchannelfeaturesoflungcancer
AT pengyujing comprehensiveinvestigationofprmt5intheprognosisandionchannelfeaturesoflungcancer